Updated Jul 21, 2026
/OpenAI, Anthropic lobbying spend climbs 23% in second quarter as legacy tech retreats/Halfpricesoft.com releases IRS Form 941 e-file add-on for ezPaycheck before July 31 deadline/Hyperscale Data discloses 1,087 Bitcoin treasury worth $70.3 million/Gross Law Firm notifies PicS N.V. shareholders of class action seeking recovery/Capline Healthcare Management says AI billing model cuts practice admin costs up to 40%/Native acquires Frontline Research Group to build AI data layer for Africa's $1.7 trillion traditional trade market/OpenAI, Anthropic lobbying spend climbs 23% in second quarter as legacy tech retreats/Halfpricesoft.com releases IRS Form 941 e-file add-on for ezPaycheck before July 31 deadline/Hyperscale Data discloses 1,087 Bitcoin treasury worth $70.3 million/Gross Law Firm notifies PicS N.V. shareholders of class action seeking recovery/Capline Healthcare Management says AI billing model cuts practice admin costs up to 40%/Native acquires Frontline Research Group to build AI data layer for Africa's $1.7 trillion traditional trade market

Novo's Wegovy Pill Still Leads the GLP-1 Pill Market as Lilly's Foundayo Launches

Novo Nordisk's Wegovy pill remains a top choice among Americans for weight loss even after the launch of Foundayo, Eli Lilly's GLP-1 pill, according to MarketWatch.

By Staff2 min readNVOLLY
Share